Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 8/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | HRH1 | P35367 | 2/20 | 0.33 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
| ▸ | CCR2 | P41597 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 2/20 | 0.32 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL730151 | 0.86 | TSHR (0.44) | TSHRCYP19A1BRD4HRH1CYP17A1 | |
| SCHEMBL16116245 | 0.80 | TBXAS1 (0.43) | TSHRCYP19A1BRD4 | |
| SCHEMBL14857830 | 0.80 | TSHR (0.39) | TSHRCYP19A1BRD4HRH1CYP17A1 | |
| SCHEMBL28562010 | 0.79 | TSHR (0.47) | TSHRCYP19A1BRD4CYP17A1 | |
| SCHEMBL5674598 | 0.79 | TAAR1 (0.47) | TSHRCYP19A1BRD4HRH1SLC6A2 | |
| Hydrochloric Acid SCHEMBL28561898 | 0.78 | TSHR (0.46) | TSHRCYP19A1BRD4CYP17A1 | |
| SCHEMBL14857787 | 0.77 | ALDH1A1 (0.41) | TSHRCYP19A1BRD4CYP17A1 | |
| SCHEMBL27621980 | 0.75 | POLB (0.45) | TSHRBRD4 | |
| SCHEMBL27984061 | 0.73 | NPC1 (0.41) | TSHRBRD4 | |
| SCHEMBL14857486 | 0.73 | TSHR (0.39) | TSHRCYP19A1BRD4HRH1CYP17A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2212328-B1 | NOVEL COMPOUNDS OF REVERSE TURN MIMETICS AND THE USE THEREOF | CHOONGWAE PHARMA CORP (KR) | 2017-01-25 | — | — | EP | disclosed |
| EP-2212330-B1 | NOVEL COMPOUNDS OF REVERSE TURN MIMETICS AND THE USE THEREOF (3) | CHOONGWAE PHARMA CORP (KR) | 2015-04-08 | — | — | EP | disclosed |
| EP-2212329-B1 | NOVEL COMPOUNDS OF REVERSE TURN MIMETICS AND THE USE THEREOF (1) | CHOONGWAE PHARMA CORP (KR) | 2014-07-30 | — | — | EP | disclosed |
| US-8138337-B2 | Reverse-turn mimetics and method relating thereto | CHOONGWAE PHARMA CORPORATION (KR) | 2012-03-20 | — | — | US | disclosed |
| US-8080657-B2 | Compounds of reverse turn mimetics and the use thereof | CHOONGWAE PHARMA CORPORATION (KR) | 2011-12-20 | — | — | US | disclosed |
| US-8071764-B2 | Compounds of reverse turn mimetics and the use thereof (2) | CHOONGWAE PHARMA CORPORATION (KR) | 2011-12-06 | — | — | US | disclosed |
| US-8049008-B2 | Reverse-turn mimetics and method relating thereto | CHOONGWAE PHARMA CORPORATION (KR) | 2011-11-01 | — | — | US | disclosed |
| US-20100286094-A1 | NOVEL COMPOUNDS OF REVERSE TURN MIMETICS AND THE USE THEREOF | CHOONGWAE PHARMA CORPORATION (KR) | 2010-11-11 | — | — | US | disclosed |
| US-20100240662-A1 | REVERSE-TURN MIMETICS AND METHOD RELATING THERETO | CHOONGWAE PHARMA CORPORATION (KR) | 2010-09-23 | — | — | US | disclosed |
| US-20100228027-A1 | NOVEL COMPOUNDS OF REVERSE TURN MIMETICS AND THE USE THEREOF (2) | CHOONGWAE PHARMA CORPORATION (KR) | 2010-09-09 | — | — | US | disclosed |
| US-20100222303-A1 | REVERSE-TURN MIMETICS AND METHOD RELATING THERETO | CHOONGWAE PHARMA CORPORATION (KR) | 2010-09-02 | — | — | US | disclosed |
| EP-2212329-A2 | NOVEL COMPOUNDS OF REVERSE TURN MIMETICS AND THE USE THEREOF (1) | Choongwae Pharma Corporation (KR) | 2010-08-04 | — | — | EP | disclosed |
| EP-2212328-A2 | NOVEL COMPOUNDS OF REVERSE TURN MIMETICS AND THE USE THEREOF (2) | Choongwae Pharma Corporation (KR) | 2010-08-04 | — | — | EP | disclosed |
| EP-2212330-A2 | NOVEL COMPOUNDS OF REVERSE TURN MIMETICS AND THE USE THEREOF (3) | Choongwae Pharma Corporation (KR) | 2010-08-04 | — | — | EP | disclosed |
| US-7671054-B1 | Reverse-turn mimetics and method relating thereto | CHOONGWAE PHARMA CORPORATION (KR) | 2010-03-02 | — | — | US | disclosed |
| WO-2009051398-A2 | NOVEL COMPOUNDS OF REVERSE TURN MIMETICS AND THE USE THEREOF (2) | CHOONGWAE PHARMA CORPORATION (KR) | 2009-04-23 | — | — | WO | disclosed |
| WO-2009051397-A2 | NOVEL COMPOUNDS OF REVERSE TURN MIMETICS AND THE USE THEREOF (3) | CHOONGWAE PHARMA CORPORATION (KR) | 2009-04-23 | — | — | WO | disclosed |
| WO-2009051399-A2 | NOVEL COMPOUNDS OF REVERSE TURN MIMETICS AND THE USE THEREOF (1) | CHOONGWAE PHARMA CORPORATION (KR) | 2009-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286094-A1 | NOVEL COMPOUNDS OF REVERSE TURN MIMETICS AND THE USE THEREOF | MCL1, MYADM, FLT3 | TSHR 3101/4885CYP19A1 4248/4885BRD4 85/4885 |
| US-20100222303-A1 | REVERSE-TURN MIMETICS AND METHOD RELATING THERETO | WNT1, WNT3, APC | TSHR 1688/4885CYP19A1 1694/4885BRD4 1562/4885 |
| US-20100228027-A1 | NOVEL COMPOUNDS OF REVERSE TURN MIMETICS AND THE USE THEREOF (2) | MCL1, BID, MYADM | TSHR 3983/4885CYP19A1 4246/4885BRD4 225/4885 |
| US-20100240662-A1 | REVERSE-TURN MIMETICS AND METHOD RELATING THERETO | WNT1, WNT3, APC | TSHR 1688/4885CYP19A1 1694/4885BRD4 1562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.